• Azza Sarfraz, Zouina Sarfraz, Muzna Sarfraz, Hinna Aftab, and Zainab Pervaiz.
• Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan
• Turk J Med Sci. 2021 Jun 28; 51 (3): 890897890-897.

Background/AimSince the outbreak of the COVID-19, numerous therapies to counteract this severe disease have emerged. The benefits of Tocilizumab for severely infected COVID-19 patients and the methodologies of ongoing clinical trials are explored.Materials And MethodsA systematic search adhering to PRISMA guidelines was conducted in PubMed, Cochrane Central, medRxiv, and bioRxiv using the following keywords: “Tocilizumab,” “Actemra,” “COVID-19.” An additional subsearch was conducted on Clinicaltrials.gov to locate ongoing tocilizumab trials.ResultsA total of 13 studies were included in the meta-analysis comprising 2120 patients. The treatment group had lower mortality compared to the control group (OR = 0.42, 95% CI = 0.26 to 0.69, P = 0.0005, I2 = 55%). A descriptive analysis of 50 registered trials was conducted.ConclusionThis review meta-analyzed the therapeutic benefits of tocilizumab in COVID-19 patients with severe disease for mortality, mechanical ventilation, and the characteristics of COVID-19 registered trials.This work is licensed under a Creative Commons Attribution 4.0 International License.

16 keywords...

hide…